News – TScan Therapeutics

About TScan
How We’re Different

Our Approach to Therapy

History of TCR Therapy

About TScan

TScan is dedicated to changing lives by discovering new cancer targets and developing safe and effective T-cell therapies for patients.
Technology
The Discovery Process

The TScan Platform

Technology

Within the tumors of cancer patients are T cells with the ability to recognize and eliminate cancer cells. We are using our proprietary target ID platform to identify the natural targets of tumor-reactive T cells and identify therapeutically active TCRs that are both safe and effective.
Pipeline
Leadership
Executive Team

Board of Directors

Scientific Advisory Board

Investors

Leadership

TScan’s experienced leadership team shares the goal of delivering groundbreaking cancer treatments to patients.
News
Contact
Contact Us

Careers

Contact

For more information about TScan, career or collaboration opportunities.

News

January 9, 2020

Astellas Venture Management, Pitango Venture Capital and Novartis Institutes for BioMedical Research Lead TScan Series B

December 9, 2019

TScan Founders Lea Hachigian and Tomasz Kula Named in Forbes 2020 “30 Under 30” List

August 12, 2019

TScan Therapeutics Announces Pioneering Publication in Scientific Journal Cell Describing New Methods to Identify Targets for T Cell Receptor Immunotherapy

July 24, 2019

TScan Therapeutics Formed to Overcome Challenges of Current Immunotherapies with Novel TCR Discovery Platform and $48 Million in Funding

1
2